Your session is about to expire
← Back to Search
Atezolizumab for Small Cell Lung Cancer
Study Summary
This trial is testing a new treatment for people with small cell lung cancer that has spread to their brain. The treatment is a combination of drugs, including a new drug called atezolizumab. The trial will last for several months, and people will be treated until their cancer progresses or they have side effects that are too severe.
- Small Cell Lung Cancer
- Brain Tumor
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You can have used steroids before to prevent nausea and vomiting caused by chemotherapy.You have excessive fluid buildup around your lungs, heart, or abdomen that requires frequent drainage. If you have a catheter in place to manage this condition, you may still be eligible.You have had a bad reaction to atezolizumab or other drugs that help the immune system fight cancer.You have a history of autoimmune disease or immune deficiency, but exceptions are made for patients with certain conditions that are well-controlled with medication. However, if you have an autoimmune-related rash that covers more than 10% of your body, you will not be eligible. You cannot have received a live vaccine within four weeks prior to starting the study or anticipate needing one during the study or within five months after the last dose. You also cannot be pregnant or breastfeeding, and you cannot have received any experimental medications within 28 days prior to starting the study.If you have another type of cancer, you can still participate as long as it's not currently getting worse and doesn't need specific treatment.
- Group 1: Study Treatment Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In how many distinct sites is this clinical experiment taking place?
"Currently, seven medical institutions are actively recruiting patients for this study; amongst them St. Vincent Anderson Regional Hospital in Anderson, City of Hope in Duarte and Nebraska Methodist Hospital in Omaha. Additionally, there are four other sites participating."
Is there currently enrolment available for this investigation?
"Unfortunately, this clinical trial is no longer recruiting. It was initially posted on May 1st 2021 and last amended on October 10th 2022. If you are searching for additional studies, there are currently 2387 trials accepting patients with brain conditions and 1437 trails involving Atezolizumab that remain open to recruitment."
Are there any historical precedents for the utilization of Atezolizumab in clinical trials?
"At this time, there are 1437 Atezolizumab-related investigations in progress with 352 taking place on Phase 3. Most of these studies are located in Shanghai but other areas have research sites as well, totaling 76634 locations."
How many individuals are currently participating in this research project?
"At the moment, this study is not accepting any more patients. It was initially posted on May 1st 2021 and last modified on October 10th 2022. However, there are 2387 clinical trials for brain-related issues and 1437 studies involving Atezolizumab actively searching for participants if you're interested in alternative options."
Has Atezolizumab been granted authorization from the FDA?
"Based on our assessment, Atezolizumab received a score of 2--indicating some data to support its safety but none backing its effectiveness. This is due to it being in the Phase 2 stage of testing."
What medical condition is Atezolizumab traditionally employed to combat?
"The administration of Atezolizumab is a common pharmacotherapy for treating illnesses such as Hodgkin's disease, mesothelioma and advanced head/neck cancer."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger